# Yoon‐Koo Kang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yoon-koo-kang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 61,587 |
| Field | Gastric Cancer Management and Outcomes |
| h-index | 95 |
| i10-index | 378 |
| Last Known Institution | Ulsan College |
| OpenAlex ID | https://openalex.org/A5005925636 |
| ORCID iD | https://orcid.org/0000-0003-0783-6583 |
| Works | 863 |

## Researcher papers

- [Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial](https://scholariq.org/papers/linifanib-versus-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer](https://scholariq.org/papers/a-phase-iii-randomized-study-of-5-fluorouracil-and-cisplatin-versus-5/)
- [Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma](https://scholariq.org/papers/four-year-overall-survival-update-from-the-phase-iii-himalaya-study-of/)
- [Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)](https://scholariq.org/papers/safety-and-efficacy-of-nivolumab-in-combination-with-s-1-capecitabine-plus/)

## Researcher topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Gastrointestinal Tumor Research and Treatment](https://scholariq.org/topics/gastrointestinal-tumor-research-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Ulsan College](https://scholariq.org/institutions/ulsan-college/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.